Company intelligence / Profile preview

IOPtima

Ownership: Private
Development stage: Commercial

Overview

IOPtima’s flagship product, the IOPtimate® system for glaucoma surgery using CO₂ laser technology, has demonstrated consistent and sustained intraocular pressure reduction with a high safety profile. Clinical feedback highlights ease of use, reduced complications compared to traditional trabeculectomy procedures, and rapid patient recovery[1].

Therapeutic areas: DermatologyOphthalmology
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

4 assets

IOPtiMate

Commercial

Indications: Glaucoma

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with global researchers and clinicians in ophthalmologyNo major pharma partnerships specifically named.

Beyond the preview

Go deeper on IOPtima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IOPtima.

Explore the full profile